These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Wang C; Pattabiraman N; Zhou JN; Fu M; Sakamaki T; Albanese C; Li Z; Wu K; Hulit J; Neumeister P; Novikoff PM; Brownlee M; Scherer PE; Jones JG; Whitney KD; Donehower LA; Harris EL; Rohan T; Johns DC; Pestell RG Mol Cell Biol; 2003 Sep; 23(17):6159-73. PubMed ID: 12917338 [TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Johnson TE; Vogel R; Rutledge SJ; Rodan G; Schmidt A Endocrinology; 1999 Jul; 140(7):3245-54. PubMed ID: 10385421 [TBL] [Abstract][Full Text] [Related]
11. Synergistic potentiation of thiazolidinedione-induced ST 13 preadipocyte differentiation by RAR synergists. Sato M; Yajima Y; Kawashima S; Tanaka K; Kagechika H Biochem Biophys Res Commun; 2001 Jan; 280(3):646-51. PubMed ID: 11162570 [TBL] [Abstract][Full Text] [Related]
12. A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. Cho MC; Lee HS; Kim JH; Choe YK; Hong JT; Paik SG; Yoon DY J Biochem Mol Biol; 2003 Mar; 36(2):207-13. PubMed ID: 12689521 [TBL] [Abstract][Full Text] [Related]
13. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Zhou G; Cummings R; Li Y; Mitra S; Wilkinson HA; Elbrecht A; Hermes JD; Schaeffer JM; Smith RG; Moller DE Mol Endocrinol; 1998 Oct; 12(10):1594-604. PubMed ID: 9773982 [TBL] [Abstract][Full Text] [Related]
14. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. Su CG; Wen X; Bailey ST; Jiang W; Rangwala SM; Keilbaugh SA; Flanigan A; Murthy S; Lazar MA; Wu GD J Clin Invest; 1999 Aug; 104(4):383-9. PubMed ID: 10449430 [TBL] [Abstract][Full Text] [Related]
15. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Westin S; Kurokawa R; Nolte RT; Wisely GB; McInerney EM; Rose DW; Milburn MV; Rosenfeld MG; Glass CK Nature; 1998 Sep; 395(6698):199-202. PubMed ID: 9744281 [TBL] [Abstract][Full Text] [Related]
16. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Tan NS; Shaw NS; Vinckenbosch N; Liu P; Yasmin R; Desvergne B; Wahli W; Noy N Mol Cell Biol; 2002 Jul; 22(14):5114-27. PubMed ID: 12077340 [TBL] [Abstract][Full Text] [Related]
17. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614 [TBL] [Abstract][Full Text] [Related]
18. Regulation of energy metabolism by long-chain fatty acids. Nakamura MT; Yudell BE; Loor JJ Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249 [TBL] [Abstract][Full Text] [Related]
19. PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Chan GK; Deckelbaum RA; Bolivar I; Goltzman D; Karaplis AC Endocrinology; 2001 Nov; 142(11):4900-9. PubMed ID: 11606458 [TBL] [Abstract][Full Text] [Related]
20. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Zhang B; Berger J; Hu E; Szalkowski D; White-Carrington S; Spiegelman BM; Moller DE Mol Endocrinol; 1996 Nov; 10(11):1457-66. PubMed ID: 8923470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]